Consultant Physician & Hepatologist
Autoimmune and Cholestatic Liver Diseases, and Liver Transplantation.
Autoimmune liver diseases include Primary Biliary Cirrhosis (PBC), Autoimmune Hepatitis (AIH) and Primary Sclerosing Cholangitis (PSC) and in combination account for 15% of the liver transplants undertaken within the UK.
Our group is focused on each of these diseases and we actively collaborate in national (UK-PBC, UK-AIH, UK-PSC) and international consortia (Global PBC and the International PSC Study Group (iPSCSG). There is an active program of biobanking in each of these diseases. We are undertaking a range of projects and have a particular interest in non-invasive assessment of disease severity and stratification of prognosis.
We have a further interest in immune mechanisms after liver transplantation in collaboration with the Institute of Immunity and Transplantation and the Renal Unit at the Royal Free.
We utilise a number of experimental approaches to examine immune cell function including human blood cells, cell line models of PID generated through targeted silencing of immune genes and murine models of PID. Our work closely collaborates with departmental and national research aimed at identifying the genes that cause PID.
I am Clinical Director for the Liver Transplantation, HPB, Hepatology, Endoscopy & Gastroenterology services at the Royal Free London NHS Trust. I am an Honorary Senior Lecturer within the Institute of Liver and Digestive Health at UCL. Our clinical service undertakes approximately 100 liver transplants per annum and we cares for over 600 patients with autoimmune and cholestatic liver diseases.
We have many research studies taking place in the department which we invite our patients to enrol for. These investigator led local, national and international studies and contract commercial studies examining new treatments.
We actively collaborate with patient groups including PSC support and the PBC Foundation including hosting a patient support meeting at the Royal Free in November 2014.
- Selected publications
- Froghi F, Koti R, Gurusamy K, Mallett S, Thorburn D, Selves L, James S, Singh J, Pinto M, Eastgate C, McNeil M, Filipe H, Jichi F, Schofield N, Martin D, Davidson B. Cardiac output Optimisation following Liver Transplant (COLT) trial: study protocol for a feasibility randomised controlled trial. Trials. 2018. 19(1):170
- Kalafateli M, Buzzetti E, Thorburn D, Davidson BR, Tsochatzis E, Gurusamy KS. Pharmacological interventions for acute hepatitis C infection: an attempted network meta-analysis. Cochrane Database Syst Rev. 2017. 3:CD011644
- Roccarina D, Majumdar A, Thorburn D, Davidson BR, Tsochatzis E, Gurusamy KS. Management of people with intermediate-stage hepatocellular carcinoma: an attempted network meta-analysis. Cochrane Database Syst Rev. 2017. 3:CD011649
- Buzzetti E, Kalafateli M, Thorburn D, Davidson BR, Tsochatzis E, Gurusamy KS. Interventions for hereditary haemochromatosis: an attempted network meta-analysis. Cochrane Database Syst Rev. 2017. 3:CD011647
- Carbone M, Sharp SJ, Flack S, Paximadas D, Spiess K, Adgey C, Griffiths L, Lim R, Trembling P, Williamson K, Wareham NJ, Aldersley M, Bathgate A, Burroughs AK, Heneghan MA, Neuberger JM, Thorburn D, Hirschfield GM, Cordell HJ, Alexander GJ, Jones DE, Sandford RN, Mells GF; UK-PBC Consortium. The UK-PBC risk scores: Derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis. Hepatology. 2016. 63(3):930-50
- Pike R, Thomas N, Workman S, Ambrose L, Guzman D, Sivakumaran S, Johnson M, Thorburn D, Harber M, Chain B, Stauss HJ. PD1-Expressing T Cell Subsets Modify the Rejection Risk in Renal Transplant Patients. Front Immunol. 2016. 7:126
- Manousou P, Cholongitas E, Samonakis D, Tsochatzis E, Corbani A, Dhillon AP, Davidson J, Rodríguez-Perálvarez M, Patch D, O'Beirne J, Thorburn D, Luong T, Rolles K, Davidson B, McCormick PA, Hayes P, Burroughs AK. Reduced fibrosis in recurrent HCV with tacrolimus, azathioprine and steroids versus tacrolimus: randomised trial long term outcomes. Gut. 2014. 63(6):1005-13
- Halliday N, Smith C, Atkinson C, O'Beirne J, Patch D, Burroughs AK, Thorburn D, Haque T. Characteristics of Epstein-Barr viraemia in adult liver transplant patients: a retrospective cohort study. Transpl Int. 2014. 27(8):838-46
- Manousou P, Burroughs AK, Tsochatzis E, Isgro G, Hall A, Green A, Calvaruso V, Ma GL, Gale J, Burgess G, O'Beirne J, Patch D, Thorburn D, Leandro G, Dhillon AP. Digital image analysis of collagen assessment of progression of fibrosis in recurrent HCV after liver transplantation. J Hepatol. 2013. 58(5):962-8
- Rodríguez-Perálvarez M, Germani G, Tsochatzis E, Rolando N, Luong TV, Dhillon AP, Thorburn D, O'Beirne J, Patch D, Burroughs AK. Predicting severity and clinical course of acute rejection after liver transplantation using blood eosinophil count. Transpl Int. 2012. 25(5):555-63.